BioPharmSignal logoBioPharmSignal

Biotech News

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

AN2 Therapeutics (ANTX)AN2 TherapeuticsCompany update

Abstracts highlight epetraborole’s potential beneficial effects on hematological profile across clinical and nonclinical studies MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 31, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and

Related news

ANTXAN2 Therapeutics2026-03-03 21:00 EST

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

ANTXAN2 Therapeutics2026-03-31 11:00 EST

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

AVIRAtea2026-05-27 11:00 EST

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

VIRIVirios Therapeutics2026-04-23 13:00 EST

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

ENTAEnanta Pharmaceuticals2026-04-13 11:00 EST

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

AVIRAtea2026-02-24 12:00 EST

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

IMNNImunon2026-09-10 13:30 EST

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

SPROSpero Therapeutics2026-07-14 11:00 EST

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

ASMBAssembly Biosciences2026-05-22 11:00 EST

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases

View all latest news

AN2 Therapeutics

Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology. Epetraborole in Polycythemia Vera AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent...

Recent company news

ANTXAN2 Therapeutics2026-09-16 21:33 EST

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

ANTXAN2 Therapeutics2026-08-31 22:00 EST

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

ANTXAN2 Therapeutics2026-08-24 11:00 EST

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

ANTXAN2 Therapeutics2026-08-11 20:00 EST

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-06-04 11:00 EST

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

Stock data

Close
4.90 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States